文献速递外周动脉疾病

肝素涂层ePTFE旁路术治疗股腘动脉闭塞所致间歇性跛行的结果

Results of infrainguinal revascularization with bypass surgery using a heparin-bonded graft for disabling intermittent claudication due to femoropopliteal occlusive disease.
PubMed 文献 · J Vasc Surg · 2019-05-18

本研究分析2002至2016年间485例因致残性间歇性跛行接受肝素涂层ePTFE旁路术的股腘动脉闭塞患者,院内死亡0.4%,主要并发症4.3%,5年一期通畅率57.7%,5年免于再手术率76.4%,流出道差和膝下吻合及术后口服抗凝药损害通畅率。

要点

  • 肝素涂层ePTFE旁路术治疗致残性间歇性跛行院内死亡0.4%,主要并发症4.3%。
  • 5年一期通畅率57.7%,5年免于再手术率76.4%,5年免于进展为严重肢体缺血率86.1%。
  • 流出道差、膝下吻合及术后口服抗凝药损害一期通畅率。

核心结论

  • 对于致残性间歇性跛行合并长段或复杂股腘动脉闭塞病变,肝素涂层ePTFE旁路术死亡率可接受。
  • 流出道差是移植物丧失通畅的显著预测因素,尤其在膝下吻合后,也是需要再手术的预测因素。
  • 双联抗血小板治疗在随访血栓方面结果显著更好,8mm移植物较6mm移植物免于再手术结果更好。

研究设计与样本

  • 回顾性分析2002至2016年1400例肝素涂层ePTFE旁路术中485例(34.6%)以间歇性跛行为指征的患者。
  • 早期主要终点为院内死亡和主要并发症,晚期主要终点为一期通畅率、免于再手术、免于进展为严重肢体缺血、免于膝上截肢或人工血管感染。

主要发现

  • 行膝上旁路术200例(41.2%),膝下旁路术231例(47.6%),胫动脉旁路术54例(11.1%)。
  • 院内死亡2例(0.4%),总主要并发症率4.3%,随访中死亡56例(11.6%)。
  • 一期通畅率12个月86.1%±1.6%(95%CI 82.7-88.9),36个月68.4%±2.4%(95%CI 63.5-72.9),60个月57.7%±2.9%(95%CI 52.0-63.2)。
  • 免于再手术率12个月96.1%±0.9%(95%CI 93.9-97.5),36个月84.8%±1.9%(95%CI 80.7-88.2),60个月76.4%±2.6%(95%CI 71.0-81.1)。
  • 60个月免于进展为严重肢体缺血率86.1%±2.2%(95%CI 81.2-89.9),膝上截肢20例(4.1%),人工血管感染7例(1.4%),60个月免于人工血管感染率98.2%±2%(95%CI 95.8-99.2)。

关键数值与推荐

  • 多因素分析显示流出道(无或1支)、远端吻合位置(膝下)和术后药物治疗(口服抗凝药)损害一期通畅率。
  • 流出道(无或1支)和移植物直径(6mm)与需要再手术显著相关。

临床怎么用

  • 对致残性间歇性跛行合并长段或复杂股腘动脉闭塞病变,可考虑肝素涂层ePTFE旁路术,需注意流出道差和膝下吻合对通畅率的影响。
  • 术后双联抗血小板治疗可能减少随访血栓,选择8mm移植物可能较6mm移植物减少再手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study was to analyze the results of infrainguinal revascularization for disabling intermittent claudication (IC) due to femoropopliteal occlusive disease using bypass graft (BPG) surgery with a heparin-bonded expanded polytetrafluoroethylene (HB-ePTFE) graft. METHODS: Between 2002 and 2016, we performed 1400 BPGs with HB-ePTFE interventions in patients with femoropopliteal occlusive disease, of which IC was an indication in 485 (34.6%) patients. Early major end points were in-hospital mortality and major complications; late major end points were primary patency, freedom from redo bypass, freedom from progression to critical limb ischemia, and freedom from above-knee amputation or prosthetic graft infection. RESULTS: We performed 200 (41.2%) above-knee BPGs and 231 (47.6%) below-knee BPGs; 54 (11.1%) BPGs targeted a tibial artery. In-hospital death occurred in two (0.4%) patients. Overall, the major complication rate was 4.3%. The median duration of follow-up was 33 months (range, 1-150 months; interquartile range [IQR], 14-62.8 months); the cumulative follow-up index for survival was 0.75 ± 0.25. During the follow-up, 56 (11.6%) patients died. Estimated primary patency of the BPG was 86.1% ± 1.6% (95% confidence interval [CI], 82.7-88.9) at 12 months, 68.4% ± 2.4% (95% CI, 63.5-72.9) at 36 months, and 57.7% ± 2.9% (95% CI, 52.0-63.2) at 60 months. On multivariate analysis, runoff status (no or one vessel), site of the distal anastomosis (below the knee), and postoperative medical treatment (oral anticoagulants) impaired primary patency. Estimated freedom from redo bypass was 96.1% ± 0.9% (95% CI, 93.9-97.5) at 12 months, 84.8% ± 1.9% (95% CI, 80.7-88.2) at 36 months, and 76.4% ± 2.6% (95% CI, 71.0-81.1) at 60 months. Both the runoff status (no or one vessel) and the diameter of the graft (6 mm) were significantly associated with the need for redo bypass. Freedom from progression to critical limb ischemia was 86.1% ± 2.2% (95% CI, 81.2-89.9) at 60 months. During the follow-up, there were 20 (4.1%) above-knee amputations, which occurred at a median of 33 months (range, 2-107 months; IQR, 14-63 months) after the indexed BPG intervention. Prosthetic graft infection occurred in seven (1.4%) patients, with a median delay from index procedure to presentation with graft infection of 33 months (range, 1-72 months; IQR, 14-62.5 months), resulting in a freedom from prosthetic graft infection rate of 98.2% ± 2% (95% CI, 95.8-99.2) at 60 months. CONCLUSIONS: In patients suffering from lifestyle-disabling IC with long or complex occlusive lesions of the femoropopliteal segment, open BPG surgery with Hb-ePTFE graft had an acceptably low mortality rate. A poor runoff status was a significant predictor of loss of graft patency, especially after a below-knee anastomosis, as was the need for redo bypass. Dual antiplatelet therapy had significantly better results against follow-up thrombosis, and 8-mm grafts showed better freedom from redo bypass compared with 6-mm grafts.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Piffaretti G, Dorigo W, Ottavi P, et al. Results of infrainguinal revascularization with bypass surgery using a heparin-bonded graft for disabling intermittent claudication due to femoropopliteal occlusive disease. J Vasc Surg. 2019. PMID: 31113719. doi:10.1016/j.jvs.2018.10.106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。